CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
primary trial objective is to demonstrate that ODM-201 produces prostate-specific antigen (PSA) response rates at 24 weeks (defined as ≥80% ...
Phase 2
Badalona, Spain and 11 other locations
to evaluate the efficacy and safety of talazoparib (PF-06944076) in combination with enzalutamide in patients with metastatic hormone-naïve prostate...
Phase 2
Barcelona, Spain and 7 other locations
This is a Phase 1/2, open-label, randomized, dose finding and dose expansion study to evaluate the safety, preliminary efficacy, and PK of gedatolisi...
Phase 1, Phase 2
Barcelona, Spain and 12 other locations
Metastatic prostate cancer is an incurable disease that typically spreads beyond the prostate. The standard of care is to ...
Phase 2, Phase 3
Barcelona, Spain and 29 other locations
The study will be conducted in 4 parts and will commence with dose escalation of AMX-500 as a monotherapy (Part 1), followed by monotherapy dose expa...
Phase 1, Phase 2
Barcelona, Spain and 7 other locations
Effects of Saruparib (AZD5305) Alone, Darolutamide Alone, and in Combination Given Prior to Radical Prostatectomy in Men with Newly Diagnosed Prostate...
Phase 1
Barcelona, Spain and 19 other locations
Evaluate the safety and tolerability of AMG 509 in adult participants and determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2...
Phase 1
Barcelona, Cataluña, Spain and 52 other locations
to as AAA617. The study also seeks to further characterize (as possible) any other serious adverse reaction(s) in the long-term in adults with prostate...
Phase 4
Barcelona, Catalunya, Spain and 53 other locations
and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have received no prior cytotoxic chemo ...
Phase 3
Barcelona, Spain and 131 other locations
docetaxel with or without local radiotherapy with or without abiraterone acetate and prednisone in patient with metastatic hormone-naïve prostate...
Phase 3
Barcelona, Spain and 76 other locations
Clinical trials
Research sites
Resources
Legal